Drug intelligence / Profile preview

SENL-B19

Development stage: Phase 2
Lead developer: Senlang Bio
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

SENL-B19 is an autologous, gene-engineered chimeric antigen receptor (CAR) T-cell therapy targeting CD19, a surface antigen expressed on B cells. Developed using a lentiviral vector to introduce the CAR gene into patient-derived T cells, it is designed to recognize and eliminate malignant B cells through direct cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC). The product is administered via infusion and aims to treat hematological malignancies such as B-cell acute lymphoblastic leukemia (B-ALL), leukemia, lymphoma, and non-Hodgkin lymphoma. The developer is Hebei Senlang Biotechnology.

Other names: autologous CD19-targeting CAR T cell therapy

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on SENL-B19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SENL-B19.

Explore the full profile